Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Pharma Company Allergan to Build New Jersey R&D Center

David Pyott (Allergan Inc.)

David Pyott (Allergan Inc.)

Allergan Inc., a developer of specialty pharmaceutical products, will build a new research and development center in Bridgewater, New Jersey. According to a company announcement, the the 93,000-square-foot facility is expected to employ “several hundred” employees, but neither the precise number nor types of the jobs were disclosed.

Allergan, headquartered in Irvine, California, develops and markets treatments for a variety of medical needs: neuroscience, ophthalmology, dermatology, and urology. The company is also a developer of breast and facial medical aesthetic products, and obesity interventions.

Allergan’s most well-known brand is Botox cosmetic, a prescription medicine (onabotulinumtoxinA) injected into facial muscles to reduce the appearance of moderate to severe vertical frown lines between the eyebrows, known as glabellar lines. In 2012, the company expects Botox to generate $1.8 billion of its total sales of $5.9 billion.

David Pyott, Allergan’s charman and CEO (pictured left), says the company plans to spend some $1 billion on R&D in 2013, of which the new facility is part. Pyott says they located in New Jersey “to benefit from the expertise of the many talented R&D professionals that reside in this state.”

The New Jersey R&D center is expected to focus on clinical development. The company lists 22 ongoing clinical trials involving eye care, urology, neuroscience, and medical aesthetics candidates.

Read more:

*     *     *

Comments are closed.